We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Saniona Ab | LSE:0RQJ | London | Ordinary Share | SE0005794617 | SANIONA AB ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 33.35 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drugs And Proprietary-whsl | 15.28M | -245.36M | -3.9329 | -8.48 | 2.08B |
Three Months Ended September 30, 2022 (2021) | Nine Months Ended September 30, 2022 (2021) |
Revenue was SEK 2.4 M (2.3 M) | Revenue was SEK 12.0 M (7.6 M) |
Operating profit/loss was SEK 21.8 M (-88.2 M)Net profit/loss was SEK 17.5 M (-93.7 M) | Operating profit/loss was SEK -203.1 M (-286.7 M)Net profit/loss was SEK -204.4 M (-281.8 M) |
Basic earnings/loss per share was SEK 0.28 (-1.50) | Basic earnings/loss per share was SEK -3.28 (-4.52) |
Diluted earnings/loss per share were SEK 0.28 (-1.50) | Diluted earnings/loss per share were SEK -3.28 (-4.52) |
Business highlights in Q3 2022
Significant events after the reporting period
Comments from the CEO “We continue to make progress on our partnering efforts and development of our pipeline in Q3 while we have reduced costs and extended runway until 2024 without having to raise additional financing. Saniona has a broad pipeline of products, a highly motivated and professional team and significant experience with partnering. I am confident that our business development efforts will help us through this difficult period for listed biotech companies and that our pipeline will deliver new valuable breakthrough medicine.” For more information, please contact Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.comThis information is such information as Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 CET on 17 November 2022.About Saniona Saniona is a clinical-stage biopharmaceutical company focused on the discovery and development of medicines modulating ion channels. The company’s most advanced product candidate, Tesomet™, has been progressed to mid-stage clinical trials for rare eating disorders. Through its ion channel expertise, Saniona is advancing two product candidates, SAN711 and SAN903. SAN711 has successfully completed a Phase 1 clinical trial for the treatment of neuropathic pain conditions. SAN903 is ready for Phase 1 clinical studies for the treatment of inflammatory and fibrotic disorders. The company has research and development partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V and Cephagenix ApS. Saniona is based in Copenhagen, Denmark, and listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.
Attachment
1 Year Saniona Ab Chart |
1 Month Saniona Ab Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions